Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer
- PMID: 28759990
- PMCID: PMC6056988
- DOI: 10.4143/crt.2017.089
Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer
Abstract
Purpose: Although sentinel lymph node biopsy (SLNB) can accurately represent the axillary lymph node (ALN) status, the false-negative rate (FNR) of SLNB is the main concern in the patients who receive SLNB alone instead of ALN dissection (ALND).
Materials and methods: We analyzed 1,886 patientswho underwent ALND after negative results of SLNB,retrospectively. A logistic regression analysis was used to identify risk factors associated with a falsenegative (FN) result. Cox regression model was used to estimate the hazard ratio of factors affecting disease-free survival (DFS).
Results: Tumor located in the upper outer portion of the breast, lymphovascular invasion, suspicious node in imaging assessment and less than three sentinel lymph nodes (SLNs) were significant independent risk factors for FN in SLNB conferring an adjusted odds ratio of 2.10 (95% confidence interval [CI], 1.30 to 3.39), 2.69 (95% CI, 1.47 to 4.91), 2.59 (95% CI, 1.62 to 4.14), and 2.39 (95% CI, 1.45 to 3.95), respectively. The prognostic factors affecting DFS were tumor size larger than 2 cm (hazard ratio [HR], 1.86; 95% CI, 1.17 to 2.96) and FN of SLNB (HR, 2.51; 95% CI, 1.42 to 4.42) in SLN-negative group (FN and true-negative), but in ALN-positive group (FN and true-positive), FN of SLNB (HR, 0.64; 95% CI, 0.33 to 1.25) did not affect DFS.
Conclusion: In patients with risk factors for a FN such as suspicious node in imaging assessment, upper outer breast cancer, less than three harvested nodes, we need attention to find another metastatic focus in non-SLNs during the operation. It may contribute to provide an exact prognosis and optimizing adjuvant treatments.
Keywords: Breast neoplasms; Prognosis; Sentinel lymph node; False negative.
Conflict of interest statement
Conflict of interest relevant to this article was not reported.
Figures
Similar articles
-
Prospective study found that peripheral lymph node sampling reduced the false-negative rate of sentinel lymph node biopsy for breast cancer.Chin J Cancer. 2016 Apr 4;35:35. doi: 10.1186/s40880-016-0099-x. Chin J Cancer. 2016. PMID: 27044285 Free PMC article.
-
Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.BMC Surg. 2015 Jun 30;15:79. doi: 10.1186/s12893-015-0067-4. BMC Surg. 2015. PMID: 26123412 Free PMC article. Clinical Trial.
-
Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.Anticancer Res. 2018 Jun;38(6):3657-3662. doi: 10.21873/anticanres.12642. Anticancer Res. 2018. PMID: 29848724
-
Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.Am J Surg. 2016 Nov;212(5):969-981. doi: 10.1016/j.amjsurg.2016.07.018. Epub 2016 Aug 16. Am J Surg. 2016. PMID: 27671032 Review.
-
Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective.Breast Cancer. 2007;14(4):362-70. doi: 10.2325/jbcs.14.362. Breast Cancer. 2007. PMID: 17986801 Review.
Cited by
-
Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer.Medicina (Kaunas). 2023 Aug 25;59(9):1544. doi: 10.3390/medicina59091544. Medicina (Kaunas). 2023. PMID: 37763661 Free PMC article. Review.
-
Validating the ACOSOG Z0011 Trial Result: A Population-Based Study Using the SEER Database.Cancers (Basel). 2020 Apr 11;12(4):950. doi: 10.3390/cancers12040950. Cancers (Basel). 2020. PMID: 32290437 Free PMC article.
-
Clinical value of postoperative sentinel lymph node biopsy.Ann Transl Med. 2019 Nov;7(22):683. doi: 10.21037/atm.2019.11.106. Ann Transl Med. 2019. PMID: 31930084 Free PMC article.
-
Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer.BMC Cancer. 2019 Oct 11;19(1):939. doi: 10.1186/s12885-019-6165-4. BMC Cancer. 2019. PMID: 31604469 Free PMC article.
-
Axillary Lymph Node Dissection Can Be Omitted in Breast Cancer Patients With Mastectomy and False-Negative Frozen Section in Sentinel Lymph Node Biopsy.Front Oncol. 2022 Apr 14;12:869864. doi: 10.3389/fonc.2022.869864. eCollection 2022. Front Oncol. 2022. PMID: 35494089 Free PMC article.
References
-
- Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. - PubMed
-
- Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53. - PubMed
-
- Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600. - PubMed
-
- Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. - PMC - PubMed
-
- van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous